RT @AurelieRheumo: JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and
Tweet Content
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal.
#LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Show on Archive Page
On
Display in Search Results
On
PDQ
Off